Tag: Blinatumomab
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per ... Read More
Amgen blood cancer drug BLINCYTO scores EC approval in pediatric patients
The European Commission (EC) has approved an expanded indication for Amgen blood cancer drug BLINCYTO (blinatumomab) as monotherapy for the treatment of certain form of ... Read More